AstraZeneca Self-Markets Nolvadex Generic; Zoladex Settlement Near
Executive Summary
AstraZeneca is marketing its own generic version of Nolvadex (tamoxifen) to protect the company from claims that it is exploiting cancer patients in the final months of exclusivity for the drug
You may also be interested in...
Barr ciprofloxacin marketing continues
Barr will continue to market authorized generic of Bayer's antibiotic Cipro (ciprofloxacin) during the product's expected pediatric exclusivity, which runs for six months beginning Dec. 9, under an amended agreement. Barr had a similar deal on AstraZeneca's breast cancer drug Nolvadex (tamoxifen) but was forced to drop its authorized generic during the pediatric exclusivity period (1"The Pink Sheet" Feb. 3, 2003, p. 13)...
Barr ciprofloxacin marketing continues
Barr will continue to market authorized generic of Bayer's antibiotic Cipro (ciprofloxacin) during the product's expected pediatric exclusivity, which runs for six months beginning Dec. 9, under an amended agreement. Barr had a similar deal on AstraZeneca's breast cancer drug Nolvadex (tamoxifen) but was forced to drop its authorized generic during the pediatric exclusivity period (1"The Pink Sheet" Feb. 3, 2003, p. 13)...
AstraZeneca Nexium Marketing Draws FTC Scrutiny; DoJ Looking At Prilosec
The Federal Trade Commission is investigating AstraZeneca's marketing of the omeprazole follow-on product Nexium